finerenone (Kerendia)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10]

Indications

* improves urine albumin/creatinine

* no effect on GFR[1]

Benefit/risk

* CKD progression: >40% decrease in eGFR relative to baseline for >4 weeks

Dosage

Tablets: 10 mg, 20 mg

Monitor

Adverse effects

* causes less hyperkalemia than spironolactone or eplerenone

* does not cause gynecomastia

Mechanism of action

Clinical trials

More general terms

References

  1. ↑ Jump up to: 1.0 1.1 Bakris GL, Agarwal R, Chan JC et al Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. A Randomized Clinical Trial JAMA. 2015;314(9):884-894 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26325557 <Internet> http://jama.jamanetwork.com/article.aspx?articleID=2432163
  2. ↑ Jump up to: 2.0 2.1 2.2 Bakris GL, Agarwal B, Anker SD et al Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020. Oct 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33264825 https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
    Ingelfinger JR, Rosen CJ Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease. N Engl J Med. 2020. Oct 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33095527 https://www.nejm.org/doi/full/10.1056/NEJMe2031382
  3. ↑ Jump up to: 3.0 3.1 Pitt B, Filippatos G, Agarwal R et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021 Aug 28; PMID: https://www.ncbi.nlm.nih.gov/pubmed/34449181 https://www.nejm.org/doi/10.1056/NEJMoa2110956
  4. ↑ Jump up to: 4.0 4.1 Pitt B, Agarwal R, Anker SD et al Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease. A FIDELITY Pooled Secondary Analysis. JAMA Netw Open. 2022;5(10):e2236123 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36287567 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797719
  5. ↑ Jump up to: 5.0 5.1 5.2 Agarwal R, Tu W, Farjat AE et al Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes. A Mediation Analysis. Ann Intern Med. 2023. Dec 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38048573 https://www.acpjournals.org/doi/10.7326/M23-1023
  6. ↑ Jump up to: 6.0 6.1 Solomon SD et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024 Sep 1; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39225278 https://www.nejm.org/doi/10.1056/NEJMoa2407107
  7. ↑ Jump up to: 7.0 7.1 Yang M, Henderson AD, Talebi A Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39520455 Free article. https://www.sciencedirect.com/science/article/pii/S0735109724085322
  8. ↑ Butt JH, Henderson AD, Jhund PS et al Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2024 Dec 4:S0735-1097(24)10423-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39665701 Free article.
  9. ↑ Jump up to: 9.0 9.1 DuBosar R Finerenone is effective for heart failure with mildly reduced or preserved ejection fraction. ACP Hospitalist. March 12, 2025 https://acphospitalist.acponline.org/archives/2025/03/12/finerenone-is-effective-for-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction.htm
    McDowell K, Docherty KF, Campbell RT et al Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2025 Mar 5:e250025. PMID: https://www.ncbi.nlm.nih.gov/pubmed/40042880 PMCID: PMC11883611 (available on 2026-03-05)
  10. ↑ Medscape: finerenone (Rx) https://reference.medscape.com/drug/kerendia-finerenone-4000168

Database

Retrieved from "https://aaushi.info/w/index.php?title=A50142&oldid=1241190"